Calendario de promoción Candel Therapeutics, Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. Más detalles| Цена ао | 1.49 |
|---|---|
| Выручка | 0.000125 |
| EBITDA | -0.0076 |
| P/S | 1829.26 |
| P/BV | 3.57 |
| EV/EBITDA | 0.6279 |
| ISIN | US1374041093 |
| Сайт | https://www.candeltx.com |
| Число акций ао | 0.02894 млрд |
| Валюта | usd |
| IPO date | 2021-07-27 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Cambio de precio por día: | -2.09% (6.71) |
|---|---|
| Cambio de precio por semana.: | -8.88% (7.21) |
| Cambio de precio por mes: | +4.12% (6.31) |
| Cambio de precio en 3 meses.: | +13.67% (5.78) |
| Cambio de precio en seis meses: | +29.08% (5.09) |
| Cambio de precio por año: | +606.45% (0.93) |
| Cambio de precio en 3 años.: | -33.84% (9.93) |
| Cambio de precio desde principios de año.: | +606.45% (0.93) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Northpond Ventures, Llc | 1935215 | 6.59 |
| Sands Capital Ventures, LLC | 811737 | 2.77 |
| Vanguard Group Inc | 425749 | 1.45 |
| FMR, LLC | 298384 | 1.02 |
| Geode Capital Management, LLC | 139253 | 0.47 |
| Bridgeway Capital Management, Inc. | 132595 | 0.45 |
| Baystate Wealth Management LLC | 76910 | 0.26 |
| Blackrock Inc. | 49285 | 0.17 |
| OneDigital Investment Advisors LLC | 29783 | 0.1 |
| State Street Corporation | 27600 | 0.09 |
| ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
|---|---|---|---|
| ProShares Hedge Replication ETF | 0.00093 | 5.9237999659878 | 1.47892 |
| iShares Micro-Cap ETF | 0.03787 | 36.318555985322 | 1.54048 |
| iShares Russell 2000 Growth ETF | 0.01119 | 38.042556988 | 0.6026 |
| ProShares UltraPro Russell2000 | 0.00323 | 89.821266282945 | 1.47873 |
| Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 39.350070246167 | 0.60264 |
| Vanguard Russell 2000 ETF | 0 | 35.648084105685 | 1.48801 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 335.27k | 1968 (56 años) |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 506.76k | 1978 (46 años) |
| Ms. Ileen B. Winick | Chief People Officer | N/A | |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | N/A | 1961 (63 año) |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer | N/A | 1969 (55 años) |
| Mr. Charles Schoch | Interim CFO, Principal Accounting Officer, Treasurer & Secretary | N/A | 1985 (39 años) |
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, CEO & Director | 1961 (63 año) |
DIRECCIÓN: United States, Needham. MA, 117 Kendrick Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.candeltx.com
Sitio web: https://www.candeltx.com
